-

CorVista Health to Present New Data on Non-Invasive Point of Care Test for Ischemia with Non-Obstructive Coronary Arteries Using Machine Learning at ACC.26

BETHESDA, Md.--(BUSINESS WIRE)--CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for ischemia with non-obstructive coronary arteries (INOCA) – a common condition, particularly in women, where patients experience cardiovascular symptoms despite having no flow-limiting blockages in their major epicardial arteries – using machine learning at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March 28-30, 2026, in New Orleans, LA.

Details of the presentations are as follows:

Title: Noninvasive Ischemia Detection in Symptomatic Patients: A Physiologic Feature Machine-Learned Model

Presenters:

  • Charles Bridges, EVP and Chief Scientific Officer, CorVista Health
  • Tim Burton, Data Scientist, CorVista Health

Format: Oral Poster

Presentation Number: Poster #78

Date and Time: Monday, March 30, 2026, at 12:30 p.m. ET – 1:30 p.m. ET

Location: Section 1590 (Ischemic Heart Diseases)

CorVista Health will be exhibiting in the Future Hub Booth #FH8, where attendees can learn about the CorVista System.

About CorVista System®

The CorVista System is an FDA-cleared, non-invasive cardiovascular diagnostics platform designed to analyze cardiac and hemodynamic signals using machine-learned algorithms. The system synchronously collects physiological signals during a brief point-of-care test and applies advanced analytics to identify patterns associated with pulmonary hypertension (PH) and coronary artery disease (CAD). The CorVista System delivers actionable diagnostic insights without the use of radiation, contrast agents, injections, fasting, or exercise. The CorVista System is developed and manufactured by Analytics For Life, Inc. and licensed to CorVista Health, Inc.

About CorVista Health

CorVista Health is dedicated to transforming cardiovascular care through innovative diagnostics that shorten the path from symptoms to diagnosis. By enabling earlier detection of complex cardiovascular conditions, CorVista aims to empower clinicians with actionable insights and improve patient outcomes across diverse care settings.

For more information on CorVista Health, please visit: www.corvista.com

Contacts

Media Contact: media@corvista.com

Industry:

CorVista Health

Release Versions
English

Contacts

Media Contact: media@corvista.com

More News From CorVista Health

Analytics for Life and CorVista Health Announce the Publication of their Cost Economic Analysis for Non-Invasive Coronary Artery Disease Testing in the Journal of Visualized Experiments

TORONTO & BETHESDA, Md.--(BUSINESS WIRE)--Today, Analytics for Life, a leading innovator in advanced point-of-care diagnostics, and CorVista Health, pioneers in non-invasive cardiac diagnostics, announced a publication of a new comprehensive cost economic analysis of their non-invasive point-of-care test for Coronary Artery Disease (CAD) in the Journal of Visualized Experiments (JoVE). The CorVista System®, a cutting-edge test for CAD, developed by Analytics for Life, is the world’s first non-i...

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

BETHESDA, Md.--(BUSINESS WIRE)--CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis, will present new data exploring the potential of a Non-Invasive Point-of-Care Rule-out Test for Heart Failure using Machine Learning at the American College of Cardiology 73rd Annual Scientific Session and Exposition in Atlanta, GA on April 7. The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of co...

Breakthrough Designated CorVista® System with Pulmonary Hypertension Add-On Cleared by FDA; Enabling Advanced Cardiovascular Testing at Point-of-Care

TORONTO & BETHESDA, Md.--(BUSINESS WIRE)--Analytics for Life, Inc. and CorVista Health Inc. announced the FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module. The CorVista® System is the first FDA-cleared, machine learned point-of-care technology for indicating the likelihood of elevated mean arterial pulmonary pressure (mPAP), an indicator of pulmonary hypertension (PH). Pulmonary hypertension is a progressive disorder that affects the blood vessels in the lungs...
Back to Newsroom